Pfizer Advances Lyme Disease Vaccine Toward Regulatory Approval

Pfizer and Valneva to seek approval for Lyme vaccine after Phase 3 trial showed over 70% efficacy, aiming to fill a major unmet medical need and diversify Pfizer's pipeline.

Pfizer is moving forward with plans to seek approval for its Lyme disease vaccine candidate, despite a nuanced outcome in its pivotal clinical trial. The pharmaceutical giant, in partnership with Valneva, is pushing ahead with regulatory submissions, banking on the vaccine's demonstrated ability to reduce infections and the significant unmet medical need in the market.

A Market Awaiting a Solution

Currently, no human vaccine for Lyme disease is approved for use. Pfizer views its candidate, PF-07307405, as addressing a substantial public health need. This strategic move also supports the company's broader initiative to diversify its product pipeline beyond its declining COVID-19-related portfolio. The upcoming regulatory filings represent a key upcoming milestone for Pfizer’s infectious disease division.

Detailed Trial Data Reveals Context for Statistical Hurdle

The Phase 3 VALOR study, which enrolled approximately 9,500 participants across North America and Europe, evaluated the vaccine co-developed with French partner Valneva. Results showed the four-dose regimen was over 70% effective in preventing confirmed Lyme disease cases.

However, the study narrowly missed its primary statistical endpoint. Pfizer clarified that this shortfall was attributable to a lower-than-projected number of actual Lyme disease infections occurring among participants during the trial period, not due to the vaccine's performance. A subsequent, pre-specified analysis confirmed the statistical significance of the vaccine's efficacy.

The treatment was reported to be well-tolerated, with no safety concerns identified during the analysis.

Partnership Terms and Financial Stakes

Under the agreement, Pfizer will hold exclusive global commercialization and manufacturing rights for the vaccine upon successful approval. In return, Valneva—in which Pfizer holds a 5.49% equity stake—is eligible to receive tiered royalties up to 22% on future sales, plus potential milestone payments totaling up to $100 million.

On the Frankfurt stock exchange, Pfizer shares closed at €23.07 on Monday. The stock has posted a moderate gain of just over 7% since the start of the year.